We believe that breakthrough scientific research drives the most transformative HealthTech innovations. We see our role as co-explorers, inspired by revolutionary ideas, partnering with outstanding scientists to redefine the way diseases are studied, diagnosed and treated.
aMoon Velocity Report

DIGITAL THERAPEUTICS

DISEASES DETECTION & TREATMENT VIA SYNTHETIC BIOLOGY

NOVEL THERAPEUTIC APPROACHES IN FIBROTIC DISEASES

**ABOUT VELOCITY**

**aMoon Velocity.**

aMoon Velocity is aMoon’s early-stage investment fund. Our investments target disruptive, cutting-edge technologies and range from sponsored research at top academic and clinical institutions, to venture formation through seed investments. aMoon. We don’t define ourselves by vertical, need, or even geographical boundaries but by our passion for partnering with entrepreneurs and scientists developing new solutions to major healthcare challenges.

We don’t define ourselves by vertical, need, or even geographical boundaries but searching for transformational solutions to healthier lives and accelerated paths for value creation and building world-leading companies.

aMoon Velocity can take an idea from inception through commercialization; we strive to help entrepreneurs see the whole road ahead and ensure we plan from the start for each company’s success.
OUR MISSION

The convergence of biology and technology has created enormous opportunities to harness transformational science and technology to confront the most pressing challenges facing modern-day health systems and practitioners.

aMoon Explorer program aims to harness pioneering scientific research globally and do-the-impossible culture to seize these unique opportunities and bring revolutionary ideas to life quickly.

We are searching for highly-disruptive, high-impact proposals for sponsored translational breakthrough academic research in three areas we believe are exciting and on the verge of a major transformation.
**WHAT ARE WE SOLVING FOR?**

**Digital therapeutics**

The arsenal of pharmacological treatments and medical devices was recently extended with the new paradigm of FDA-regulated digital agents.

Software-based therapeutics rely on a combination of inputs, AI, and machine learning to generate effective outputs providing diagnosis and contact-less intervention against multiple diseases. Ranging from cardio-metabolic diseases to neurological and behavioral diseases, evidence-based behavioral changes are increasingly recognized for their safety and efficacy.

**WHAT WE ARE LOOKING FOR?**

- A software-based therapeutic for a recognized medical condition.
- A product sold to physicians and/or consumers/patients.

**OUT OF OUR CURRENT SCOPE**

- A wearable, electronic or electrical device.
- An interventional agent or process.
- A software-based disease management tool (an app, a website, etc.) which is not intended to treat a disease.

**Disease Detection and Treatment via Synthetic Biology**

Technological advances in fields such as DNA sequencing and multi-omics, together with dramatic reductions in the price of biological building blocks are ushering in an era of exciting discoveries in Synthetic Biology. Whether “editing” existing biological systems with new capabilities, or combining natural and synthetic building blocks into a newly conceived system, this field is poised to further our understanding and coping with human disease in a fundamental way.

**WHAT WE ARE LOOKING FOR?**

- Novel approaches for diagnosis and/or treatment of diseases of major unmet clinical need utilizing synthetic biologics, cells, machines and their combinations.
- Novel platforms for generating synthetic mimetics of naturally occurring components in tissues, cells and biologics.
- Synthetic/engineered biological systems recapitulating natural systems.

**OUT OF OUR CURRENT SCOPE**

- Biological computers.
- Cell-based drug delivery platforms.
Novel Therapeutic Approaches in Fibrotic Diseases

Human fibrotic diseases constitute a major health problem worldwide. The knowledge of the fibrotic process pathogenesis and etiology is still incomplete. The absence of appropriate and fully validated biomarkers prevents timely diagnoses and there are no effective disease-modifying therapeutic agents approved.

Pulmonary, renal and hepatic fibrosis are among the more common fibrotic diseases, which in aggregate represent a major unmet clinical need.

WHAT WE ARE LOOKING FOR?

• Novel findings related to fibrotic etiology.
• Novel mechanisms of action translatable to potential slowing down or reversal of fibrotic processes.
• Novel chemical/biological entities with therapeutic potential in fibrotic diseases.

OUT OF OUR CURRENT SCOPE

• Existing fibrosis-related pathways and therapeutics.
• Proposals for the repurposing of known chemical/biological entities to fibrosis therapeutics.
The Explorer Program

THE EXPLORER PROGRAM
The aMoon Program will remain open from May 25th, 2021 until June 30th, 2021 at 17:00 (GMT+2).

1 to 3 projects will be selected to participate in this program and will receive development and strategic support, as well as $150,000 (500,000 NIS) funding. Sponsored projects must last a maximum of 12 months. Institutional matching funds are a plus.

Selected projects will be assigned development managers from the aMoon team that will provide teams with mentoring and guidance throughout the program period. Academic project teams and their Development Managers will work together to define the goals/deliverables of the sponsored research and monitor the progress towards these goals during the period.

aMoon will be given a first right to in-license necessary background and research results into a new company, all subject to pre-agreed terms with the researcher and their institution.

WHO CAN APPLY?
The call is open to academic teams in Academic Institutions including Universities, Research Institutes, Hospitals and Colleges. Teams involving more than one institution are encouraged to apply.

HOW TO APPLY?
Register at the Program’s website and complete the application electronically in English before June 30th 2021, at 17:00 (GMT+2). The application process involves the submission of: A 15 slides pitch deck covering specific areas such as rational for development, relevant experimental data, IP information, proposed work plan and use of funds for the sponsored period.

EVALUATION PROCESS
The selection of funded projects will be based on the quality of submission, novelty of the proposed idea, fit with the published theme, and the potential of the proposed program to reach a meaningful outcome within the time and funding of the call.
THE EVALUATION PROCESS WILL CONSIST OF THREE STAGES

Eligibility Check
A first review will be performed by the aMoon Evaluation Committee to identify applications that fulfill the initial criteria of the Program.

Experts Evaluation
Several experts will join the aMoon team in the in-depth evaluation of the applications.

Pitch Day
Submissions selected following the first two evaluation stages will be invited to present the proposal to the aMoon Evaluation Committee. 1 to 3 proposals will be selected for the Program.

Utmost confidentiality will be maintained throughout the process.